Minerva NeurosciencesNERV
Market Cap: $19.7M
About: Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Employees: 9
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
22% more capital invested
Capital invested by funds: $5.44M [Q1] → $6.65M (+$1.21M) [Q2]
0.35% less ownership
Funds ownership: 30.19% [Q1] → 29.85% (-0.35%) [Q2]
5% less funds holding
Funds holding: 21 [Q1] → 20 (-1) [Q2]
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Douglas Tsao 57% 1-year accuracy 74 / 129 met price target | 78%upside $5 | Neutral Maintained | 7 Aug 2024 |